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Abstract
The biological role and therapeutic potential of long non-coding RNAs (lncRNAs) in multiple myeloma (MM) are still to be
investigated. Here, we studied the functional signiﬁcance and the druggability of the oncogenic lncRNA MALAT1 in MM.
Targeting MALAT1 by novel LNA-gapmeR antisense oligonucleotide antagonized MM cell proliferation and triggered
apoptosis both in vitro and in vivo in a murine xenograft model of human MM. Of note, antagonism of MALAT1
downmodulated the two major transcriptional activators of proteasome subunit genes, namely NRF1 and NRF2, and resulted
in reduced trypsin, chymotrypsin and caspase-like proteasome activities and in accumulation of polyubiquitinated proteins.
NRF1 and NRF2 decrease upon MALAT1 targeting was due to transcriptional activation of their negative regulator KEAP1,
and resulted in reduced expression of anti-oxidant genes and increased ROS levels. In turn, NRF1 promoted MALAT1
expression thus establishing a positive feedback loop. Our ﬁndings demonstrate a crucial role of MALAT1 in the regulation
of the proteasome machinery, and provide proof-of-concept that its targeting is a novel powerful option for the treatment of
MM.
Introduction
Multiple myeloma (MM) is a B-cell malignancy char-
acterized by abnormal proliferation of plasma cells (PCs)
within the bone marrow (BM). Despite increased knowl-
edge on the pathobiology of MM and the approval of new
therapeutics, MM is still an incurable disease with a 5 years
overall survival rate of about 45% [1].
Over the past decade, functional genomics and epige-
nomics studies have demonstrated that, similar to protein-
coding genes, short non-coding RNAs are dysregulated and
play key roles in the pathogenesis of human cancers [2, 3],
including MM [4]. Notably, over half of the human genome
is transcribed as long non-coding RNAs (lncRNAs), this
term referring to non-coding transcripts longer than 200
nucleotides [5]. LncRNAs regulate gene transcription and
mRNA translation by different mechanisms, including
interaction with RNA-binding proteins, epigenetic mod-
iﬁcation of gene expression, or microRNA modulation [6].
Therefore, it is not surprising that lncRNAs are implicated
in relevant biological processes such as development,
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differentiation, apoptosis, and cell cycle, and are dysregu-
lated in cancer [7]. Consistently, it is becoming clear that
lncRNAs may act as oncogenes or tumor suppressors [8],
and may represent potential druggable targets [9].
Dysregulation of lncRNAs in the hematopoietic com-
partment has been proven to contribute to the onset of
malignancies [10].
The metastasis-associated lung adenocarcinoma tran-
script 1 (MALAT1) is an evolutionarily conserved lncRNA,
that plays a critical role both in the maintenance of the
undifferentiated status of hematopoietic stem cells [11] and
in B-cell activation [12]. By expression proﬁling of
lncRNAs in PC dyscrasias, we previously demonstrated
high expression of MALAT1 associated with onset of the
disease and progression from normal PCs to overt MM [13].
MALAT1 has been found overexpressed in a wide variety
of other hematological malignancies and solid tumors [14].
The high expression of MALAT1 in MM, along with its
involvement in well-established cancer-associated pathways
[14, 15], points to a role of this lncRNA in MM
pathogenesis.
Here we characterized the biological sequelae of
MALAT1 in MM, and we reported the ﬁrst evidence of its
druggability by a novel LNA gapmeR antisense oligonu-
cleotide (ASO), which could lead to signiﬁcant therapeutic
advances in MM and other tumors.
Materials and methods
Cell cultures, drugs, and ASOs/siRNAs
Detailed information is provided in Supplementary
Methods.
Microarray gene expression proﬁling
See Supplementary Methods for protocols.
Cell viability, proliferation, and migration assays
Cell viability was analyzed by Cell Titer-Glo (CTG; Pro-
mega), and S-phase DNA synthesis by BrdU Cell Pro-
liferation assay (Cell Signaling Technology). For colony-
forming assay, 200 cells were plated in triplicate in 1 ml of
mixture composed of 1.1% methylcellulose (MethoCultTM
STEMCELL Technologies) in RPMI-1640+ 10% FBS.
Crystal violet-stained colonies were scored after 2 weeks
under an inverted microscope (Leica DM IL LED) at ×5
magniﬁcation. Cell migration was analyzed by Transwell
migration assay (BD Biosciences) as described [16].
Luciferase assays
For proteasome, ARE-Reporter, and ROS Luciferase
Assays see Supplementary Methods.
Plasmids, transfection, and transduction of MM cells
Plasmids used and related procedures are reported in Sup-
plementary Methods.
Quantitative real-time PCR
RNA extraction and quantitative real-time PCR (qRT-PCR)
were performed as described [17]. Procedures are in Sup-
plementary Methods.
Western blot and antibodies
Whole cell protein extracts were prepared using NP40
containing Halt Protease Inhibitor cocktail (Invitrogen,
Thermo Scientiﬁc). Western blot (WB) was performed as
reported [18] (Supplementary Methods).
Chromatin and RNA immunoprecipitation
For chromatin immunoprecipitation (ChIP) experiments, the
Pierce Agarose ChIP Assay Kit (Thermo Fisher Scientiﬁc)
was used. RNA immunoprecipitation (RIP) was performed
using Imprint® RNA Immunoprecipitation Kit (Sigma
Aldrich); see Supplementary Methods for protocols.
In vivo study
The MM xenograft model used is described in Supplemen-
tary Methods.
Immunohistochemistry and immunoﬂuorescence
See Supplementary Methods.
Statistical analysis
Each experiment was performed at least three times, and
values were reported as mean ± SD. Data were analyzed
using Student's t tests for two group comparisons or a one-
way analysis of variance (ANOVA) for multiple compar-
isons using the Graphpad software (GraphPad Software, La
Jolla, CA, USA). P-value < 0.05 was considered signiﬁcant.
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Fig. 1 Effects of MALAT1 manipulation on in vitro and in vivo MM
growth. a MALAT1 relative levels (left panel) and cell viability of
MM cells (right panel) were determined by qRT-PCR and CTG assay
respectively, 4 days after treatment with 5 μM g CNT or g#5. b CTG
assay in MM cell lines and primary PCs co-cultured on HS-5 stromal
cells, and treated for 4 days with 5 μM g CNT or g#5. c Colony
formation assay performed on MM cell lines treated for 14 days with 5
μM g CNT or g#5; representative pictures of colonies at day 14 are
also shown. d Annexin V staining of MM cell lines, 5 days after
treatment with naked g CNT or g#5. Data are representative of at least
three independent experiments. e Caliper measurements of tumor
volumes in mice bearing AMO-ABZB-luc xenografts IP-treated with g
CNT (25 mg/kg) or g#5. *p < 0.05
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Results
MALAT1 regulates growth and survival in MM cell
lines and primary cells
We ﬁrst interrogated three microarray datasets and observed
increasing expression of MALAT1 in PCs from MGUS,
SMM and overt MM as compared to normal PCs (Sup-
plementary Fig. S1a). To evaluate the potential prognostic
value of MALAT1 in MM, we analyzed both a clinically
annotated proprietary dataset and the large TT2/TT3 trials
cohort from the University of Arkansas encompassing more
than 550 patients. However, we did not ﬁnd any signiﬁcant
correlation between MALAT1 expression and overall sur-
vival or time to relapse (Supplementary Fig. S1b-c).
To investigate the role of MALAT1 in MM, we exploited
both gain and loss of function approaches. Ectopic
expression of MALAT1 increased viability, proliferation,
and migration of low MALAT1 expressing AMO-1 cells
(Supplementary Fig. S1d), and the same effects were
observed in bortezomib-resistant AMO-BZB cells (Sup-
plementary Fig. S2a-c). MALAT1-dependent proliferative
advantage was supported by activation of oncogenic
pathways, as demonstrated by the increase in phosphory-
lated AKT, p65-NF-κB, ERK1/2, and CREB (Supplemen-
tary Fig. S2d). To knock-down (KD) MALAT1, we used
novel LNA-gapmeR ASOs, that trigger RNAse-H-
dependent degradation of lncRNAs [19]. Transfection of
two different LNA-gapmeRs targeting MALAT1 (hence-
forth referred to as g#5 and g#9) signiﬁcantly reduced
MALAT1 expression, and this effect translated into reduced
viability and migration of tumor cells (Supplementary Fig.
S3a-c). Transfection of MALAT1-targeting siRNAs also
reduced MM cell viability (Supplementary Fig. S3d),
although to a lesser extent than LNA-gapmeRs. At micro-
molar concentration, naked LNA-gapmeRs passively cross
the plasma membrane (gymnosis) [20]. We thus evaluated
the sensitivity to naked g#5 of human MM cell lines and
primary patient CD138+ MM cells. After 96 h of exposure
to g#5, a potent downregulation of MALAT1 was observed,
with a parallel decrease in cell viability (Fig. 1a); con-
versely, PBMCs from healthy donors were not sensitive to
g#5 (Supplementary Fig. S3e), thus suggesting a favorable
therapeutic index. Importantly, exogenous MALAT1
expression completely rescued the effects of g#5 on cell
viability (Fig. S3f). We next evaluated g#5 effects in the
Fig. 2 MALAT1 depletion reduces proteasome gene expression in
MM cells. a GSEA performed 48 h after transfection with 50 nM g
CNT or g#5 (nominal p-values for RPMI-8226 and MM1s were 0.00
and 0.028, respectively). b Caspase-like (C-L), Trypsin-like (T-L),
Chimotrypsin-like (CT-L) activities evaluated by proteasome assay
(Promega), 4 days after delivery of naked gCNT or g#5; WB of
polyubiquitinated (Ub) proteins is reported on the right. c WB of ER
stress markers 4 days after delivery of naked gCNT or g#5. *= p <
0.05
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context of the BM milieu [21]: treatment with
g#5 suppressed the viability of MM cell lines or patient-
derived MM cells co-cultured on HS-5 cells, without any
effect on HS-5 viability (Fig. 1b; MALAT1 expression in
patient MM cells is reported in Supplementary Fig. S3g).
Moreover, exogenous cytokines did not counteract g#5
effect on cell viability (Supplementary Fig. S3h). G#5
treatment dramatically suppressed the clonogenicity of MM
cells (Fig. 1c), while MALAT1 overexpression increased
colony formation (Supplementary Fig. S3i).
Caspase-dependent induction of MM cell death by
MALAT1 inhibition in vitro and in vivo
To uncover the biological scenario underlying cytotoxicity
of MALAT1 inhibition, we analyzed the effects of g#5
treatment on cell cycle and apoptosis. After 72 h, g#5
altered cell cycle proﬁle, with a remarkable inhibition of S-
phase (Supplementary Fig. S3l), which was conﬁrmed by
reduced BrdU uptake (Supplementary Fig. S3m). Prolonged
exposure of MM cells to g#5 up to 5 days triggered
apoptotic cell death (Fig. 1d); both intrinsic and extrinsic
apoptotic pathways were induced in MM cell lines and
primary patient CD138+ MM cells by g#5, as assessed by
WB (Supplementary Fig. S3n). Exposure to pan-caspase
inhibitor zVAD-FMK reverted g#5-inhibitory effects on
cell viability (Supplementary Fig. S3o).
Finally, we analyzed the effect of g#5 treatment in vivo,
in a murine xenograft model of human MM. Treatment
doses were selected based on in vitro activity of g#5 and on
similar LNA ASOs [22]. Notably, g#5 reduced the growth
of AMO-BZB-luc xenografts (Fig. 1e and Fig. S4a); on-
target activity of g#5 in vivo was conﬁrmed by reduced
MALAT1 levels in resected tumor samples after g#5
treatment (Supplementary Fig. S4b). H&E staining of mice
vital organs did not highlight any change in tissue archi-
tecture (Supplementary Fig. S4c); lack of toxicity was also
supported by the absence of neurological changes or weight
loss of treated animals (data not shown). Importantly,
increase in caspase-3 on g#5-treated xenografts conﬁrmed
apoptosis induction (Supplementary Fig. S4d).
Fig. 3 MALAT1 regulates NRF1 and NRF2 expression and activity. a
WB of NRF1, NRF2, and PSMβ5 in MM cell lines or patient-derived
MM cells, 5 days after delivery of naked g CNT or g#5. b CTG
viability assay was performed in AMO-BZB cells transfected with 2.5
μg of NRF1-ﬂag or NRF2-ﬂag expression vectors, then treated for
4 days with 2.5 μM naked g#5. c Luciferase assay performed in cells
transfected with an ARE reporter (Promega), and then treated for
4 days with 5.0 μM g CNT or naked g#5. d ROS measurement by
luminescent assay, 4 days after delivery of 5.0 μM naked g CNT or
g#5. e Representative immunoﬂuorescence of γH2AX foci, 4 days
after delivery of g CNT (5.0 μM) or g#5 (×63 magniﬁcation). Data are
representative of at least three independent experiments. *p < 0.05
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Identiﬁcation of proteasome-associated genes as
targets of MALAT1 in MM
In order to identify MALAT1 targets unveiling its func-
tional role, we carried out gene expression proﬁling in two
MM cell lines after MALAT1 KD. GSEA identiﬁed the
proteasome as the only pathway downregulated by g#5
(Fig. 2a). Using qRT-PCR and WB, we conﬁrmed reduced
expression of selected proteasome subunits as well as of
proteasome maturation protein (POMP), responsible for
assembly of β subunit rings [23], upon g#5 treatment
(Supplementary Fig. S5a-b); similar results were obtained
after transfection of MALAT1-targeting siRNAs (Supple-
mentary Fig. S5c). Trypsine-like, chymotrypsin-like, and
caspase-like proteasome activities were also signiﬁcantly
inhibited by g#5, resulting in accumulation of poly-
ubiquitinated proteins (Fig. 2b); conversely, proteasome
activities were augmented by MALAT1 overexpression
(Supplementary Fig.S5d). These data suggest a role of
MALAT1 in the proteasome pathway. To conﬁrm in vitro
data, we evaluated gene expression signatures associated
with MALAT1 expression in primary MM cells. MM
patients were divided in four groups according to MALAT1
expression. Functional enrichment analysis of genes dif-
ferentially expressed between the two groups with high (I
quartile) and low (IV quartile) MALAT1 (Supplementary
Fig. S5e) showed signiﬁcant enrichment of the proteasome
pathway in high MALAT1 group (Supplementary Table
S1), strengthening the role of MALAT1 in proteasome
modulation.
Accumulation of polyubiquitinated proteins induces
endoplasmic reticulum (ER) stress and triggers the unfolded
protein response [24]. G#5 treatment increased phosphor-
ylation of eIF2a, and induced ER stress sensor proteins such
as inositol-requiring enzyme 1α (IRE1α), the protein kinase
R (PRKR)-like ER kinase (PERK), the chaperone BiP/
Fig. 4 MALAT1 epigenetically regulates KEAP1. a qRT-PCR of
KEAP1 mRNA relative expression, 5 days after delivery of naked g
CNT or g#5; right panel shows WB of KEAP1. b qRT-PCR of KEAP1
and EZH2 mRNA levels in AMO-BZB cells, 24 h after transfection
with 100 nM of the corresponding siRNAs. c qPCR for KEAP1 pro-
moter performed after ChIP with H3K27Me3 antibody, in AMO-BZB
cells treated for 72 h with 2.5 μM naked g#5 or 2 μM DZNep. Data are
representative of at least three independent experiments. *p < 0.05
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GRP78, the Activating Transcription Factor 4 (ATF4), and
the UPR-induced proapoptotic CCAAT/enhancer-binding
protein (C/EBP) homologous protein (CHOP) (Fig. 2c).
These results suggest that ER stress-induced apoptosis may
contribute to cytotoxicity of g#5.
MALAT1 regulates NRF1/2 signaling pathway
Our results indicate that inhibition of MALAT1 is asso-
ciated with a decrease in both proteasome subunit mRNA
levels and proteasome activity. NRF1 and NRF2 are key
transcription factors that control proteasome gene expres-
sion in cells upon binding to Antioxidant Response Element
(ARE)-bearing promoters [25–27]; accordingly, we
observed reduced expression of proteasome-associated
Fig. 5 NRF1 induces MALAT1 expression in a clinically relevant
feedback loop. a qPCR for MALAT1 promoter performed after ChIP
with an NRF1 antibody or IgG control. b Luciferase assay carried out
in AMO-BZB cells, 48 h after transfection with MALAT1 promoter
reporter (2.5 μg), together with 2.5 μg of NRF1 (V-NRF1), NRF2 (V-
NRF2), or empty vector (V-CNT). c Cartoon illustrating the regulatory
loop identiﬁed in this study. d qRT-PCR of MALAT1 and NRF1, 24 h
after bortezomib treatment. CTG viability assay performed in AMO-1
cells (e) and in AMO-BZB cells (f), 4 days after treatment with g#5
and bortezomib. *p < 0.05; °combination index < 1.0 (calculated using
Calcusyn)
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genes in MM cells transfected with NRF1 and
NRF2 siRNAs (Supplementary Fig.S6a-b), and corre-
sponding decrease of MM cell viability (Supplementary
Fig.S6c). We hypothesized that NRF1 and NRF2 might be
involved in MALAT1-dependent regulation of proteasome
gene expression. WB indicated a signiﬁcant impact of
MALAT1 inhibition and/or overexpression on the protein
levels of NRF1 and NRF2; importantly, downregulation of
NRF1, NRF2, and PSMβ5 proteins was also conﬁrmed in
primary CD138+ MM cells treated ex vivo with g#5
(Fig. 3a and Fig. S6d). Ectopic NRF1 and NRF2 abrogated
g#5-induced downregulation of PSMβ5 mRNA (Fig. S6e-f)
and rescued the effects on MM cell viability (Fig. 3b),
suggesting a signiﬁcant role of NRF1/2 on the oncogenic
potential of MALAT1 in MM.
NRF1 and NRF2 are involved in ROS detoxiﬁcation by
activating ARE-bearing anti-oxidant genes’ promoters [28].
Consistent with NRF1 and NRF2 downregulation, g#5
inhibited the activity of an ARE-driven reporter (Fig. 3c),
downregulated mRNAs of antioxidant genes (Supplemen-
tary Fig.S7a), and enhanced ROS production (Fig. 3d).
Elevated oxidative stress is present in cancer cells, and
excessive ROS may promote DNA damage [29]. Of note,
g#5 increased DNA damage of MM cells, evidenced by
increased γH2AX phosphorylation (Supplementary Fig.
S7b) and accumulation of γH2AX nuclear foci (Fig. 3e) in
MALAT1-depleted cells. These data indicate that MALAT1
antagonism inhibits NRF1/2 expression and activity in MM
cells.
MALAT1 epigenetically regulates the NRF1/2-
negative regulator KEAP1
NRF1/2 protein turn-over in tumor cells is controlled by the
kelck-like EZH-associated protein 1 (KEAP1) and other
ubiquitin ligase complexes [30, 31]. In AMO-BZB cells,
transfection of KEAP1-targeting siRNAs upregulated both
NRF1 and NRF2 proteins, as well as PSMβ5 subunit
(Supplementary Fig. S8), thus supporting a negative role of
KEAP1 on NRF1 and NRF2 stability in MM cells.
Importantly, KEAP1 mRNA and protein levels resulted
upregulated upon g#5 treatment (Fig. 4a), while reduced by
ectopic MALAT1 (Supplementary Fig. S9). Since interac-
tion of MALAT1 with EZH2 has been proven to negatively
impact gene expression [32], we asked whether MALAT1
could epigenetically regulate KEAP1. Using a RIP assay,
ﬁrstly we conﬁrmed a physical interaction between EZH2
and MALAT1 in MM cells (Supplementary Fig. S10).
Similar to g#5, genetic (via EZH2-siRNAs; Fig.4b) or
pharmacological (via DZNep; Supplementary Fig.S11a)
inhibition of EZH2 resulted in KEAP1 upregulation.
Importantly, inhibition of either EZH2 or MALAT1 by
DZNep and g#5 respectively, displaced H3K27me3 from
the KEAP1 promoter, as assessed by ChIP (Fig. 4c). Finally,
ectopic expression of EZH2 abrogated g#5-induced upre-
gulation of KEAP1 mRNA (Fig. S11b). Collectively, these
results indicate that MALAT1 cooperates with EZH2 to
repress KEAP1 transcription, and suggest that MALAT1
inhibition may target the proteasome in MM cells by
upregulating KEAP1, which negatively impacts NRF1 and
NRF2 expression.
NRF1 and MALAT1 establish a feedback loop with
clinical signiﬁcance
In silico search of TF binding sites within MALAT1 pro-
moter revealed a putative NRF1 consensus (Supplementary
Fig. S12). Indeed, using a ChIP assay, we observed sig-
niﬁcant enrichment of NRF1 at MALAT1 promoter
(Fig. 5a); moreover, ectopic expression of NRF1, but not
NRF2, transactivated MALAT1 promoter (Fig. 5b), as
shown by luciferase reporter assays. Finally, silencing of
NRF1 resulted in MALAT1 downregulation in MM cells,
while no effect was observed in NRF2-silenced cells (Fig.
S13a). Collectively, these data support the mutual regula-
tion of MALAT1 and NRF1 within a regulatory loop ulti-
mately impacting the proteasome machinery (Fig. 5c). To
evaluate the clinical signiﬁcance of this loop, ﬁrstly we
analyzed NRF1 and MALAT1 expression in isogenic
AMO-1 cell lines treated with bortezomib. Interestingly,
bortezomib downregulated MALAT1 and NRF1 only in
AMO-1 bortezomib-sensitive (Fig. 5d; Fig.S13b), indicat-
ing that MALAT1/NRF1 loop is overactivated in drug-
resistant cells. To decipher the role of MALAT1 in borte-
zomib sensitivity, we combined g#5 with bortezomib and
evaluated effects on cell viability: notably, g#5 enhanced
bortezomib activity on AMO-1 (Fig. 5e) and on MM
patient-derived primary PCs (Fig. S13c), and overcame
bortezomib resistance in AMO-BZB cells (Fig. 5f). These
data indicate that g#5 disrupts MALAT1/NRF1 loop and its
combination with bortezomib triggers synergistic
cytotoxicity.
Discussion
An unprecedented boom of research has recently demon-
strated dysregulation of short ncRNAs in MM, and their
potential as therapeutic targets [2, 4]; conversely, the role of
lncRNAs in MM pathobiology remains to be elucidated.
In this study, we investigated and functionally char-
acterized MALAT1, a nuclear-localized lncRNA highly
expressed in MM [13]. The tumor-promoting role of
MALAT1 has been demonstrated in a variety of solid
malignancies, where it modulates essential pathways
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promoting proliferation, escape from apoptosis, migration
and invasion [15].
Importantly, we observed MALAT1 progressively
upregulated in PCs from MGUS, SMM and overt MM
patients as compared to normal PCs, suggesting a potential
role in MM pathogenesis; however, we failed to demon-
strate any signiﬁcant association between MALAT1
expression and the clinical outcome in two available clini-
cally annotated datasets tested.
We also performed a comprehensive analysis of the
molecular perturbations produced by MALAT1 in MM
cells, providing the ﬁrst evidence of its potential as ther-
apeutic target in MM. To efﬁciently target MALAT1, we
used a novel LNA gapmeR ASO, that represents a unique
tool to KD lncRNAs, even more efﬁciently than RNA
interference [33]. LNA gapmeR ASOs have a central DNA
gap that binds the RNA target, and triggers its RNase H-
dependent degradation; the presence of phosphorothioate
confers nuclease resistance in body ﬂuids [34], while LNA
increases afﬁnity to the target [19]. ASOs are nowadays
becoming an attractive therapeutic modality to target
undruggable pathways [35]. In this light, we here demon-
strated that gymnotic delivery of MALAT1-targeting 16mer
LNA gapmeR g#5 is a potent anti-MM agent that decreases
cell proliferation even in the presence of the BM milieu, and
triggers apoptosis in both MM cell lines and patient-derived
PCs. The translational relevance of our ﬁndings is under-
scored by signiﬁcant anti-tumor activity of g#5 in a
humanized murine model of MM, along with optimal tumor
uptake and no evidence of systemic toxicity.
By transcriptome analysis, we found that g#5 down-
modulated proteasome gene expression, and enrichment of
proteasome pathway genes was observed in vivo in high
MALAT1 MM patients. The proteasome is a multi-catalytic
proteinase complex, responsible for degradation of
damaged and misfolded ubiquitinated proteins [36]. Pro-
teasome inhibition prefentially kills malignant cells, and
represents the most clinically relevant target therapy in MM
[37]. Intriguingly, g#5 treatment led to inhibition of all three
proteasome catalytic activities, along with accumulation of
polyubiquitinated proteins. Mechanistically, MALAT1-
dependent proteasome regulation occurred via the NRF1-
2/KEAP1 pathway. NRF1 and NRF2 are known transcrip-
tional activators of proteasome genes [25–27]. As in other
cancer types [15, 32], MALAT1 was found to interact with
the methyltransferase EZH2 also in MM cells, and both
MALAT1 and EZH2 inhibitors reduced H3K27Me3 at
KEAP1 promoter, thus upregulating KEAP1 mRNA. As a
consequence, inhibition of MALAT1 decreased the
expression and activity of KEAP1 targets NRF1 and NRF2.
Finally, NRF1 was found to bind to and transactivate
MALAT1 promoter, providing evidence of a novel reg-
ulatory loop in MM cells, whose targeting by g#5 enhanced
bortezomib anti-tumor activity both in drug sensitive and
resistant MM cells.
MALAT1 targeting may therefore provide a novel
strategy to simultaneously block all the proteasome catalytic
activities. It is tempting to speculate that g#5 might confer
therapeutic advantage when compensatory hyperactivation
of trypsine and caspase-like activities emerge as a con-
sequence of bortezomib resistance [38].
In conclusion, our study sheds light on a novel
MALAT1-dependent regulation of MM proteasome
machinery, and provides the ﬁrst pre-clinical demonstration
of a unique effective MALAT1-targeting ASO as new
powerful therapeutic agent for MM treatment.
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